Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]N. D. Wong: Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol, 11(5), 276-89 (2014)

  • [2]Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 385(9963), 117-71 (2015)

  • [3]A. E. Moran, M. H. Forouzanfar, G. A. Roth, G. A. Mensah, M. Ezzati, C. J. Murray and M. Naghavi: Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation, 129(14), 1483-92 (2014)

  • [4]A. E. Moran, M. H. Forouzanfar, G. A. Roth, G. A. Mensah, M. Ezzati: The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation, 129(14), 1493-501 (2014)

  • [5]A. E. Moran, J. T. Oliver, M. Mirzaie, M. H. Forouzanfar, M. Chilov Assessing the Global Burden of Ischemic Heart Disease: Part1: Methods for a Systematic Review of the Global Epidemiology of Ischemic Heart Disease in 1990 and 2010. Glob Heart, 7(4), 315-329 (2012)

  • [6]N. Oba, R. McCaffrey, P. Choonhapran, P. Chutug and S. Rueangram: Development of a community participation program for diabetes mellitus prevention in a primary care unit, Thailand. Nurs Health Sci, 13(3), 352-9 (2011)

  • [7]A. Vaidya, P. K. Pokharel, S. Nagesh, P. Karki, S. Kumar and S. Majhi: Prevalence of coronary heart disease in the urban adult males of eastern Nepal: a population-based analytical cross-sectional study. Indian Heart J, 61(4), 341-7 (2009)

  • [8]M. Grau, V. Bongard, M. Fito, J. B. Ruidavets, J. Sala, D. Taraszkiewicz: Prevalence of cardiovascular risk factors in men with stable coronary heart disease in France and Spain. Arch Cardiovasc Dis, 103(2), 80-9 (2010)

  • [9]M. C. Kontos, D. B. Diercks and J. D. Kirk: Emergency department and office-based evaluation of patients with chest pain. Mayo Clin Proc, 85(3), 284-99 (2010)

  • [10]S. Kaukola: The diagonal ear-lobe crease, a physical sign associated with coronary heart disease. Acta Med Scand Suppl, 619, 1-49 (1978)

  • [11]T. F. Luscher, A. von Eckardstein and B. Simic: Therapeutic targets to raise HDL in patients at risk or with coronary artery disease. Curr Vasc Pharmacol, 10(6), 720-4 (2012)

  • [12]P. de Araujo Goncalves, H. M. Garcia-Garcia, M. S. Carvalho, H. Dores: Diabetes as an independent predictor of high atherosclerotic burden assessed by coronary computed tomography angiography: the coronary artery disease equivalent revisited. Int J Cardiovasc Imaging, 29(5), 1105-14 (2013)

  • [13]Y. Li, X. M. Wang, Y. L. Liu, K. Shi, Y. F. Yang and Y. H. Guo: [Risk factors for coronary artery lesions in children with Kawasaki disease]. Zhongguo Dang Dai Er Ke Za Zhi, 14(12), 938-41 (2012)

  • [14]N. Mahalle, M. V. Kulkarni and S. S. Naik: Is hypomagnesaemia a coronary risk factor among Indians with coronary artery disease? J Cardiovasc Dis Res, 3(4), 280-6 (2012)

  • [15]N. Koitabashi and M. Kurabayashi: Stroke and cardiovascular disease related with hypertriglyceridemia. Nihon Rinsho, 71(9), 1606-10 (2013)

  • [16]B. G. Talayero and F. M. Sacks: The role of triglycerides in atherosclerosis. Curr Cardiol Rep, 13(6), 544-52(2011) doi:10.1007/s11886-011-0220-3

  • [17]G. Ambrosio and I. Tritto: Interaction between the endothelium and blood cells in acute coronary syndromes. Ital Heart J, 2 Suppl 3, 43S-44S (2001)

  • [18]S. Kinlay, A. P. Selwyn, P. Libby and P. Ganz: Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol, 32 Suppl 3, S62-6 (1998)

  • [19]A. Tuttolomondo, D. Di Raimondo, R. Pecoraro, V. Arnao, A. Pinto and G. Licata: Atherosclerosis as an inflammatory disease. Curr Pharm Des, 18(28), 4266-88 (2012)

  • [20]A. Abbate, A. C. Morton and D. C. Crossman: Anti-inflammatory therapies in myocardial infarction. Lancet, 385(9987), 2573-4 (2015)

  • [21]M. R. Bacci, J. A. Santos and L. F. Nogueira: Coronary stent stenosis in acute myocardial infarction. BMJ Case Rep, 2013 (2013)

  • [22]N. H. Pijls: Acute myocardial infarction and underlying stenosis severity. Am J Cardiol, 103(9), 1204-5 (2009)

  • [23]K. Tanaka and M. Sata: Atherosclerosis: progress in diagnosis and treatments. Topics: II. Atherosclerosis-promoting factors; pathogenesis and pathophysiology; 3. From basic research: focusing on large and peripheral vessels. Nihon Naika Gakkai Zasshi, 102(2), 305-12 (2013)

  • [24]H. Plasschaert, S. Heeneman and M. J. Daemen: Progression in atherosclerosis: histological features and pathophysiology of atherosclerotic lesions. Top Magn Reson Imaging, 20(4), 227-37 (2009)

  • [25]K. Sakakura, M. Nakano, F. Otsuka, E. Ladich, F. D. Kolodgie and R. Virmani: Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ, 22(6), 399-411 (2013)

  • [26]D. Tousoulis, A. M. Kampoli, N. Papageorgiou, E. Androulakis, C. Antoniades: Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des, 17(37), 4089-110 (2011)

  • [27]P. Libby, P. M. Ridker and G. K. Hansson: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol, 54(23), 2129-38 (2009)

  • [28]A. D’Souza, M. Hussain, F. C. Howarth, N. M. Woods: Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. Mol Cell Biochem, 331(1-2), 89-116 (2009)

  • [29]V. Mallika, B. Goswami and M. Rajappa: Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology, 58(5), 513-22 (2007)

  • [30]M. F. Lopes-Virella and G. Virella: Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb, 20(10), 743-54 (2013)

  • [31]I. Peluso, G. Morabito, L. Urban, F. Ioannone and M. Serafini: Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr Metab Immune Disord Drug Targets, 12(4), 351-60 (2012)

  • [32]A. Hovland, K. T. Lappegard and T. E. Mollnes: LDL apheresis and inflammation--implications for atherosclerosis. Scand J Immunol, 76(3), 229-36 (2012)

  • [33]R. L. Wilensky, Y. Shi, E. R. Mohler, 3rd, D. Hamamdzic, M. E. Burgert: Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med, 14(10), 1059-66 (2008)

  • [34]R. S. Rosenson, M. Vracar-Grabar and I. Helenowski: Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids. Cardiovasc Drugs Ther, 22(1), 55-8 (2008)

  • [35]K. M. Patel, A. Strong, J. Tohyama, X. Jin, C. R. Morales: Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis. Circ Res, 116(5), 789-96(2015)

  • [36]D. Rott, J. Zhu, Y. F. Zhou, M. S. Burnett, A. Zalles-Ganley and S. E. Epstein: IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis, 170(2), 223-8 (2003)

  • [37]J. Fruebis, V. Gonzalez, M. Silvestre and W. Palinski: Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol, 17(7), 1289-302 (1997)

  • [38]M. Drechsler, J. Duchene and O. Soehnlein: Chemokines control mobilization, recruitment, and fate of monocytes in atherosclerosis. Arterioscler Thromb Vasc Biol, 35(5), 1050-5 (2015)

  • [39]E. Butoi, A. M. Gan and I. Manduteanu: Molecular and functional interactions among monocytes/macrophages and smooth muscle cells and their relevance for atherosclerosis. Crit Rev Eukaryot Gene Expr, 24(4), 341-55 (2014)

  • [40]A. Roessner, A. Herrera, H. J. Honing, E. Vollmer, G. Zwadlo, R. Schurmann, C. Sorg and E. Grundmann: Identification of macrophages and smooth muscle cells with monoclonal antibodies in the human atherosclerotic plaque. Virchows Arch A Pathol Anat Histopathol, 412(2), 169-74 (1987)

  • [41]J. F. Zhao, L. C. Ching, Y. C. Huang, C. Y. Chen, A. N. Chiang: Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol Nutr Food Res, 56(5), 691-701 (2012)

  • [42]Y. Yuan, P. Li and J. Ye: Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. Protein Cell, 3(3), 173-81 (2012)

  • [43]N. R. Webb and K. J. Moore: Macrophage-derived foam cells in atherosclerosis: lessons from murine models and implications for therapy. Curr Drug Targets, 8(12), 1249-63 (2007)

  • [44]Z. J. Cheng, H. Vapaatalo and E. Mervaala: Angiotensin II and vascular inflammation. Med Sci Monit, 11(6), RA194-205 (2005)

  • [45]H. S. Lim, D. Felmeden and G. Y. Lip: Angiotensin II-mediated vascular inflammation: the balance between vascular endothelial growth factor and angiopoietins. Hypertension, 45(2), e3 (2005)

  • [46]C. R. Tirapelli, D. Bonaventura, L. F. Tirapelli and A. M. de Oliveira: Mechanisms underlying the vascular actions of endothelin 1, angiotensin II and bradykinin in the rat carotid. Pharmacology, 84(2), 111-26 (2009)

  • [47]S. J. Hwang, C. M. Ballantyne, A. R. Sharrett, L. C. Smith: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation, 96(12), 4219-25 (1997)

  • [48]A. K. Stannard, R. Khurana, I. M. Evans, V. Sofra, D. I. Holmes and I. Zachary: Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol, 27(3), 494-502 (2007)

  • [49]Y. Wang, L. Wang, X. Ai, J. Zhao, X. Hao, Y. Lu and Z. Qiao: Nicotine could augment adhesion molecule expression in human endothelial cells through macrophages secreting TNF-alpha, IL-1beta. Int Immunopharmacol, 4(13), 1675-86 (2004)

  • [50]X. Zhang, X. Liu, H. Shang, Y. Xu and M. Qian: Monocyte chemoattractant protein-1 induces endothelial cell apoptosis in vitro through a p53-dependent mitochondrial pathway. Acta Biochim Biophys Sin (Shanghai), 43(10), 787-95 (2011)

  • [51]G. Virella, D. Atchley, S. Koskinen, D. Zheng and M. F. Lopes-Virella: Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol, 105(1), 81-92 (2002)

  • [52]I. Kriszbacher, M. Koppan and J. Bodis: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 353(4), 429-30; author reply 429-30 (2005)

  • [53]C. Weber and H. Noels: Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 17(11), 1410-22 (2011)

  • [54]H. Li, M. I. Cybulsky, M. A. Gimbrone, Jr. and P. Libby: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb, 13(2), 197-204 (1993)

  • [55]C. Antoniades, C. Bakogiannis, D. Tousoulis, A. S. Antonopoulos and C. Stefanadis: The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol, 54(8), 669-77 (2009)

  • [56]M. Yuan, H. Fu, L. Ren, H. Wang and W. Guo: Soluble CD40 ligand promotes macrophage foam cell formation in the etiology of atherosclerosis. Cardiology, 131(1), 1-12(2015)

  • [57]M. B. Pepys and G. M. Hirschfield: C-reactive protein: a critical update. J Clin Invest, 111(12), 1805-12 (2003)

  • [58]Y. Wu, L. A. Potempa, D. El Kebir and J. G. Filep: C-reactive protein and inflammation: conformational changes affect function. Biol Chem (2015)

  • [59]L. H. Kuller, R. P. Tracy, J. Shaten and E. N. Meilahn: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol, 144(6), 537-47 (1996)

  • [60]R. Rajtar, W. Kolasinska-Kloch and M. Kloch: (C-reactive protein in patients with coronary heart disease). Folia Med Cracov, 45(1-2), 25-32 (2004)

  • [61]G. Latkovskis, N. Licis and U. Kalnins: C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet, 31(5), 207-13 (2004)

  • [62]M. Kivimaki and I. Kawachi: Regarding the relationship between the inflammatory marker C-reactive protein and coronary heart disease. Am J Epidemiol, 178(1), 154-5 (2013)

  • [63]P. M. Ridker, W. Koenig and V. Fuster: C-reactive protein and coronary heart disease. N Engl J Med, 351(3), 295-8; author reply 295-8 (2004)

  • [64]K. Sakai, M. Yasuda, K. Tomooka and M. Nobunaga: (Activation mechanism and reaction process of the complement system--the classical pathway). Nihon Rinsho, 37(5), 943-55 (1979)

  • [65]R. R. Porter and K. B. Reid: Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv Protein Chem, 33, 1-71 (1979)

  • [66]C. Bentley, W. Fries and V. Brade: Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro. Immunology, 35(6), 971-80 (1978)

  • [67]T. Fujita: Activation pathway of complement (classical, alternative, lectin). Nihon Rinsho, 63 Suppl 4, 269-73 (2005)

  • [68]J. E. Volanakis and M. H. Kaplan: Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol, 113(1), 9-17 (1974)

  • [69]K. Yasojima, C. Schwab, E. G. McGeer and P. L. McGeer: Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol, 21(7), 1214-9 (2001)

  • [70]K. Yasojima, C. Schwab, E. G. McGeer and P. L. McGeer: Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol, 158(3), 1039-51 (2001)

  • [71]S. R. Marder, D. E. Chenoweth, I. M. Goldstein and H. D. Perez: Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol, 134(5), 3325-31 (1985)

  • [72]S. O’Barr and N. R. Cooper: The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer’s disease. J Neuroimmunol, 109(2), 87-94 (2000)

  • [73]H. Ali: Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett, 128(1), 36-45 (2010)

  • [74]H. G. Rus, F. Niculescu, E. Constantinescu, A. Cristea and R. Vlaicu: Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis, 61(1), 35-42 (1986)

  • [75]R. Vlaicu, F. Niculescu, H. G. Rus and A. Cristea: Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis, 57(2-3), 163-77 (1985)

  • [76]J. Mauer, J. L. Denson and J. C. Bruning: Versatile functions for IL-6 in metabolism and cancer. Trends Immunol, 36(2), 92-101 (2015)

  • [77]T. Taga, M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano and T. Kishimoto: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58(3), 573-81 (1989)

  • [78]T. Kubota and A. Yokoyama: Interleukin-6 (IL-6)/soluble IL-6 receptor(sIL-6R). Nihon Rinsho, 68 Suppl 7, 75-7 (2010)

  • [79]M. Kaneda, T. Odaka, H. Suetake, D. Tahara and T. Miyadai: Teleost IL-6 promotes antibody production through STAT3 signaling via IL-6R and gp130. Dev Comp Immunol, 38(2), 224-31 (2012)

  • [80]F. Legendre, J. Dudhia, J. P. Pujol and P. Bogdanowicz: JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem, 278(5), 2903-12 (2003)

  • [81]K. Murakami-Mori, T. Taga, T. Kishimoto and S. Nakamura: The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi’s sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth. Int Immunol, 8(4), 595-602 (1996)

  • [82]J. Mauer, B. Chaurasia, J. Goldau, M. C. Vogt, J. Ruud, K. D. Nguyen: Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol, 15(5), 423-30 (2014)

  • [83]G. B. Lim: Coronary artery disease: IL-6 signaling linked with CHD. Nat Rev Cardiol, 9(6), 313(2012)

  • [84]X. W. Jia, Y. P. Tian, Y. Wang, X. X. Deng and Z. N. Dong: Correlation of polymorphism in IL-6 gene promoter with BMI, inflammatory factors, and pathogenesis and progression of CHD. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15(6), 1270-5 (2007)

  • [85]K. M. Beavers, D. P. Beavers, J. J. Newman, A. M. Andersonr: Effects of total and regional fat loss on plasma CRP and IL-6 in overweight and obese, older adults with knee osteoarthritis. Osteoarthritis Cartilage, 23(2), 249-56 (2015)

  • [86]E. Bernberg, M. A. Ulleryd, M. E. Johansson and G. M. Bergstrom: Social disruption stress increases IL-6 levels and accelerates atherosclerosis in ApoE-/-mice. Atherosclerosis, 221(2), 359-65 (2012)

  • [87]K. Ganeshan and P. J. Bryce: Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-beta. J Immunol, 188(2), 594-603 (2012)

  • [88]J. M. Stapp, V. Sjoelund, H. A. Lassiter, R. C. Feldhoff and P. W. Feldhoff: Recombinant rat IL-1beta and IL-6 synergistically enhance C3 mRNA levels and complement component C3 secretion by H-35 rat hepatoma cells. Cytokine, 30(2), 78-85 (2005)

  • [89]R. D. Ye and L. Sun: Emerging functions of serum amyloid A in inflammation. J Leukoc Biol (2015)

  • [90]Y. Lv, X. Zhang, Y. Sun and S. Zhang: Activation of NF-kappaB contributes to production of pig-major acute protein and serum amyloid A in pigs experimentally infected with porcine circovirus type 2. Res Vet Sci, 95(3), 1235-40 (2013)

  • [91]J. R. Delanghe, M. R. Langlois, D. De Bacquer, R. Mak, P. Capel, L. Van Renterghem and G. De Backer: Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis, 160(2), 471-6 (2002)

  • [92]B. D. Johnson, K. E. Kip, O. C. Marroquin, P. M. Ridker: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation, 109(6), 726-32 (2004)

  • [93]T. S. Harb, W. Zareba, A. J. Moss, P. M. Ridker, V. J. Marder, N. Rifai: Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol, 89(2), 216-21 (2002)

  • [94]S. X. Anand, J. F. Viles-Gonzalez, J. J. Badimon, E. Cavusoglu and J. D. Marmur: Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost, 90(3), 377-84 (2003)

  • [95]U. Schonbeck and P. Libby: The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci, 58(1), 4-43 (2001)

  • [96]R. J. Armitage, W. C. Fanslow, L. Strockbine, T. A. Sato.: Molecular and biological characterization of a murine ligand for CD40. Nature, 357(6373), 80-2 (1992)

  • [97]F. Mach, U. Schonbeck, G. K. Sukhova, E. Atkinson and P. Libby: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 394(6689), 200-3(1998)

  • [98]S. Hoving, S. Heeneman, M. J. Gijbels, J. A. te Poele, J. F. Pol, K. Gabriels: Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. Radiother Oncol, 101(1), 100-8 (2011)

  • [99]I. Erturan, B. K. Koroglu, A. Adiloglu, A. M. Ceyhan: Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study. Int J Dermatol, 53(4), 503-9 (2014)

  • [100]B. L. Xu, C. H. Bei, R. Wang and X. X. Lei: Serum sCD40L detection for risk evaluation of acute coronary syndromes. Nan Fang Yi Ke Da Xue Xue Bao, 26(11), 1656-7 (2006)

  • [101]B. Pamukcu, G. Y. Lip, V. Snezhitskiy and E. Shantsila: The CD40-CD40L system in cardiovascular disease. Ann Med, 43(5), 331-40(2011)

  • [102]N. Sato, K. Kashima, Y. Tanaka, H. Shimizu and M. Mori: Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes, 46(1), 133-7 (1997)

  • [103]C. Liu, G. Xie, W. Huang, Y. Yang, P. Li and Z. Tu: Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and High LDL-C levels in CHD patients. J Atheroscler Thromb, 19(5), 435-43 (2012)

  • [104]K. Yunoki, T. Naruko, M. Inaba, T. Inoue, M. Nakagawa, K. Sugioka. Becker and M. Ueda: Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. Atherosclerosis, 231(2), 308-14 (2013)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review

Inflammatory biomarkers of coronary heart disease

Hongyu Li 1, Kai Sun 2, Ruiping Zhao 1,*, Jiang Hu 3, Zhiru Hao 1, Fei Wang 1, Yaojun Lu 1, Fu Liu 1, Yong Zhang 1
Affiliations
Article Info

1 Department of Cardiology, Baotou Central Hospital, Baotou, China

2 Department of Radiology, Baotou Central Hospital, Baotou, China

3 Department of Surgery, Baotou Central Hospital, Baotou, China

Abstract

Coronary heart disease (CHD), characterized by inflammation and accumulation of plaques mainly comprised of lipids, calcium and inflammatory cells in the walls of coronary arteries. CHD is exacerbated by specific cardiovascular risk factors, such as obesity, diabetes mellitus, and hypertension. The current review focuses on the critical role of traditional inflammatory biomarkers, including interleukin-6, C-reactive protein (CRP), complement, CD40 and myeloperoxidase (MPO), in the pathogenesis of CHD.

Keywords

  • Coronary heart disease
  • atherosclerosis
  • inflammation
  • C-reactive protein
  • review

References